China on the Cusp of Anticancer Biosimilar Wave, Report Says

March 31, 2020
Tony Hagen
Tony Hagen

China’s biosimilar development engine is supercharged and running on octane, a recent report said.

China has lagged in the adoption of anticancer biosimilars, but a huge number of agents in development suggest an “incoming wave” of these agents is about to hit, according to authors of a recent study.

Just 2 anticancer biosimilars were approved in China by the end of 2019, but the country has 23.9% of the global cancer burden. The turning point in China could occur very soon, the authors said, noting that 54 anticancer biosimilars representing 7 reference products are under clinical development in mainland China, 3 are involved in new drug application reviews, and 27 are in late-phase efficacy comparative studies.

These findings were included in a report of biosimilar adoption in 40 countries with 78.1% of the worldwide cancer incidence. China’s biosimilar development engine is supercharged and running on octane, the report said.

Visit The Center for Biosimilars for the full story.